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Levels Correlate with Better Outcomes
Sung W. Choi,1 Patrick Stiff,2 Kenneth Cooke,3 James L. M. Ferrara,1 Thomas Braun,4
Carrie Kitko,1 Pavan Reddy,1 Gregory Yanik,1 Shin Mineishi,1 Sophie Paczesny,1
David Hanauer,5 Attaphol Pawarode,1 Edward Peres,1 Tulio Rodriguez,2
Scott Smith,2 John E. Levine1Graft-versus-host disease (GVHD) causes most non-relapse mortality (NRM) after alternative donor (unre-
lated and mismatched related) hematopoietic cell transplant (HCT). We previously showed that increases in
day17 TNF-receptor-1 (TNFR1) ratios (posttransplantation day17/pretransplantation baseline) after mye-
loablative HCT correlate with outcomes including GVHD, NRM, and survival. Therefore, we conducted
a phase II trial at 2 centers, testing whether the addition of the TNF-inhibitor etanercept (25 mg twice weekly
from start of conditioning to day 156) to standard GVHD prophylaxis would lower TNFR1 levels, reduce
GVHD rates, and improve NRM and survival. Patients underwent myeloablative HCT from a matched
unrelated donor (URD; N 5 71), 1-antigen mismatched URD (N 5 26), or 1-antigen mismatched related
donor (N5 3) using either total body irradiation (TBI)-based conditioning (N5 29) or non-TBI-based con-
ditioning (N 5 71). Compared to historical controls, the increase in posttransplantation day 17 TNFR1
ratios was not altered in patients who received TBI-based conditioning, but was 40% lower in patients
receiving non-TBI-based conditioning. The latter group experienced relatively low rates of severe grade 3
to 4 GVHD (14%), 1-year NRM (16%), and high 1-year survival (69%). These findings suggest that (1) the
effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating
the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes.
Biol Blood Marrow Transplant 18: 1525-1532 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: GVHD, Hematopoietic cell transplantation, TNF-a, TNFR1INTRODUCTION
Allogeneic hematopoietic cell transplant (allo-
HCT) is an important therapeutic option for a variety
of malignant and nonmalignant conditions. One bar-
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6/j.bbmt.2012.03.013outcomes when donors other than HLA-matched
siblings are used [1,2]. Compared with matched
related donors, recipients of matched or single
antigen mismatched unrelated donor (URD) and
mismatched related donor transplantations are at
a significantly increased risk of non-relapse mortality
(NRM) [3,4]. The major contributor to NRM is
acute graft-versus-host disease (aGVHD), which de-
velops in 50% to 70% of recipients receiving these
type of grafts despite standard immunosuppressive
prophylaxis [5-8]. Thus, novel GVHD prophylaxis
strategies that successfully attenuate aGVHD-related
mortality without increasing other causes of NRM or
relapse are needed.
TNF-alpha (TNF-a) plays an important role in the
inflammatory cascade that ultimately evolves to
aGVHD [9], and thus represents a potential target for
preemptive treatment in the control of GVHD. We
have previously shown that in the first week after mye-
loablative hematopoietic cell transplant (HCT), the
magnitude of change in the TNF-receptor-1 (TNFR1)
ratio (posttransplantation day 17/pretransplantation1525
Table 1. Patient Characteristics for Patients Who Un-
derwent Myeloablative Allogeneic Transplantation and Re-
ceived Etanercept in Addition to Standard GVHD Prophylaxis
from 2005 to 2009
Characteristics No. of Patients
Sample size 100
Age
Median, yr 47
Range 2-61
Gender
Male 57
Female 43
Disease status at transplantation*
Low risk 39
Intermediate risk 33
High risk 28
Donor source
8/8 matched unrelated 71
7/8 mismatched unrelated 26
7/8 mismatched related 3
Stem cell source
Peripheral blood 96
Bone marrow 4
Conditioning regimen†
Non-TBI 71
Busulfan-based
FluBu4 37
BuCy ± cytarabine 26
BCNU-based
CVB 7
BEAM 1
1526 Biol Blood Marrow Transplant 18:1525-1532, 2012S. W. Choi et al.baseline), a surrogate for TNF-a, strongly correlates
with important transplantation outcomes such as
GVHD, NRM, and overall survival (OS) [10]. We re-
ported that 161 patients who underwent myeloablative
URD HCT followed by GVHD prophylaxis, consist-
ing of the widely utilized regimen of a calcineurin
inhibitor and mini-methotrexate, experienced a near
doubling of TNFR1 levels at day 17 posttransplanta-
tion (median 1.84  baseline, mean 2.4  baseline).
This increase likely reflected the combination of
conditioning-induced tissue damage together with
release of TNF-a by activated components of the
immune system [5,11].
Given that TNF-a amplifies the early alloreactive
response in allo-HCT [12], we investigated whether
TNF-inhibition could attenuate this pathway. Etaner-
cept consists of 2 recombinant human TNFR (p75)
monomers fused to the Fc portion of human Ig G1,
binds to TNF-a, and renders it inactive [13]. We
tested the hypothesis that addition of etanercept to
standard GVHD prophylaxis would lower TNFR1 ra-
tios and thereby reduce severe GVHD and subsequent
NRM, improving OS in patients after transplantations
from unrelated and partially matched related donor
transplantations.TBI 29
Diagnosis
Malignant 97
Acute myelogenous leukemia 38
Myelodysplastic syndrome 9
Acute lymphoblastic leukemia 19
Myeloproliferative disease‡ 7
Non-Hodgkin lymphoma 20
Myelofibrosis 2
Multiple myeloma 2
Nonmalignant 3
TBI indicates total body irradiation; FluBu4, fludarabine and busulfan;
BuCy, busulfan and cyclophosphamide; BCNU, carmustine.
*Disease classifications correspond to the Center for International
Blood and Marrow Transplant Research Request for Information
Disease Classifications Form (www.cibmtr.org).
†‘‘FluBu4,’’ fludarabine 40 mg/m2 i.v. daily for 4 days and busulfan 3.2 mg/
kg i.v. daily for 4 days; ‘‘BuCy,’’ busulfan 3.2 mg/kg i.v. daily for 4 days and
cyclophosphamide (either 60 mg/kg i.v. daily for 2 days or in children, 50
mg/kg i.v. daily for 4 days)6 cytarabine 2000 mg/m2 i.v. twice daily for 2
days; ‘‘CVB,’’ cyclophosphamide 1800 mg/m2 i.v. daily for 4 days, etopo-
side (VP-16) 200 mg/m2 i.v. every 12 hours for 4 days, and carmustine
(BCNU) 450 mg/m2 i.v. daily for 1 day; and ‘‘BEAM,’’ BCNU 300 mg/
m2 i.v. for 1 day, etoposide 100 mg/m2 i.v. twice daily together with cy-
tarabine 200 mg/m2 i.v. twice daily for 4 days and melphalan 140 mg/m2
i.v. for 1 day; ‘‘CyTBI,’’ cyclophosphamide 60 mg/kg i.v. daily for 2 days
and total body irradiation (TBI) 200 cGy twice daily for 3 days.
‡Myeloproliferative diseases: chronic myelogenous leukemia (N 5 5);
chronic myelomonocytic leukemia (N 5 1); juvenile myelomonocytic
leukemia (N 5 1).METHODS
Study Cohort
Patients .1 year of age who were candidates for
a myeloablative allo-HCT were eligible for inclusion.
Donors and recipients were required to match for 7/8
or 8/8 HLA-A, HLA-B, HLA-C, and HLA-DRB1
loci. Patients with an 8/8 HLA-matched related donor
were not eligible. Mid-resolution DNA typing was
performed for all class I loci. Allelic typing by high-
resolution DNA sequencing defined a match at
DRB1. Patients with progressivemalignancies were in-
eligible. Patients with uncontrolled infection despite
treatment with appropriate anti-infectives were also
ineligible. The protocol and informed consents were
approved by the Institutional Review Board at theUni-
versity of Michigan and Loyola University Medical
Center. All patients or their legal guardians signed in-
formed consents in accordance with the Declaration
of Helsinki.
Cytokine Analysis
Plasma samples collected pretransplantation (base-
line) and day 17 after allo-HCT were frozen for later
analysis. TNFR1 levels were measured in duplicate us-
ing an enzyme-linked immunosorbent assay according
to the manufacturer’s protocol (R&D Systems, Min-
neapolis, MN). Enzyme-linked immunosorbent assay
plates were read by a microplate reader (Bio-Rad,
Hercules, CA).Study Design
The study was conducted at 2 institutions as an
open-label phase II clinical trial. All patients received
a myeloablative conditioning regimen (Table 1) se-
lected by the treating physician on the basis of under-
lying disease, age, degree of donor match, and disease
status at the time of transplantation.
Biol Blood Marrow Transplant 18:1525-1532, 2012 1527TNF-Inhibition for GVHD PreventionGVHD prophylaxis consisted of tacrolimus initi-
ated on day 23 (titrated to a goal level of 8-12 ng/
mL) and mini-methotrexate administered at a dose of
5 mg/m2 i.v. on days11,13,16, and 111. In the ab-
sence of aGVHD, tacrolimus was tapered starting on
day 156 posttransplantation by 25% per month so
that it was discontinued by day 1180 posttransplanta-
tion. The first dose of study drug, etanercept (0.4 mg/
kg, maximum dose 25 mg), was administered subcuta-
neously within 24 hours of initiation of the condition-
ing regimen. The subsequent doses were administered
twice weekly (at least 72 hours apart) through day156
for a total of 18 to 19 doses depending on the length of
conditioning regimen. Doses were not modified based
upon hepatic or renal function. However, doses were
held for persistent bacteremia, hemodynamic instabil-
ity, or fever above 100.5F for more than 5 days and
not restarted until resolution. Additionally, if the cyto-
megalovirus (CMV) viral load increased after 72 hours
of anti-CMV treatment, etanercept was held until im-
provement in the viral load was documented. Addi-
tional doses of etanercept were not administered if
more than 2 consecutive doses were held for any rea-
son. Etanercept was discontinued and patients were re-
placed if early relapse of the underlying malignancy
occurred within day 121.
Supportive care therapies were administered ac-
cording to institutional guidelines. Antimicrobial pro-
phylaxis included levofloxacin 500 mg once daily for
prevention of bacterial infections, voriconazole 200
mg twice daily, acyclovir 400 mg twice daily, and sul-
famethoxazole/trimethoprim or pentamidine for pre-
vention of pneumocystis carinii pneumonia. Pediatric
patients received age/weight equivalent dosing of anti-
biotics. CMV DNA was monitored weekly by quanti-
tative PCR [14] and preemptive therapy with antiviral
agents begun in the event of a positive assay. The i.v. Ig
400 mg/kg replacement therapy was given for IgG
levels \400 mg/dL. Total body irradiation (TBI)-
treated patients at Loyola University Medical Center
(N 5 9) also received palifermin for mucositis protec-
tion according to the institutional guidelines.
Infections through Day 100
An infection was defined using the following crite-
ria: one ormore positive blood and/or fluid cultures, or
the detection of DNA in the plasma by quantitative
PCR. CMV disease was defined as an organ infected
by CMV [15]. Proven, probable, and possible invasive
fungal infections were classified according to interna-
tional consensus criteria up to day1180 or relapse [16].
GVHD Scoring
The aGVHD was scored weekly by the modified
Glucksberg criteria [17]. Biopsies were obtained of in-
volved target organs to confirm the diagnosis ofaGVHD. Clinically significant aGVHD was treated
with methylprednisolone 2 mg/kg/day orally or by
i.v. Etanercept was continued during therapy for
aGVHD. Complete response to therapy was defined
as the resolution of all manifestations of GVHD (all
target organs stage 0). Chronic GVHD (cGVHD)
was evaluated according to the National Institutes of
Health consensus criteria [18].Statistical Analysis
The study was originally designed to enroll 80 pa-
tients in order to have sufficient power to detect a 50%
decrease in NRM and a 20% decrease in aGVHD
compared with historical rates at our centers. After it
was recognized that etanercept was not benefiting pa-
tients receiving TBI-based conditioning, the protocol
was amended to exclude patients receiving TBI-based
conditioning. Accrual was extended to 100 patients to
provide sufficient power to detect a 50% decrease in
NRM in the non-TBI-conditioned patients compared
with historical NRM rates for these patients at our
centers. Differences in median day 17 TNFR1 ratios
between study and control patients were assessed using
a Wilcoxon rank sum test. The control patients con-
sisted of 161 previously reported patients who under-
went myeloablative URD HCT at the University of
Michigan between 2000 and 2005. They received
GVHD prophylaxis consisting of the widely utilized
regimen of a calcineurin inhibitor and mini-
methotrexate [10]. Study patients were significantly
older (median age 47 versus 38 years; P 5 .004), but
otherwise were not statistically different from the con-
trol patients with respect to disease treated, match, and
use of TBI. OS was estimated with the methods of
Kaplan and Meier [19]. The cumulative incidence of
NRM and aGVHD were adjusted for competing risks
and estimated using Gray’s method [20]. The associa-
tion of day 17 TNFR1 ratios with clinical outcomes
was assessed with Cox regression (OS) and competing
risks regression (NRM/aGVHD), with relapse treated
as a competing risk. Multivariate models included
TNFR1 ratio and age at transplantation as continuous
variables and categorical variables for conditioning
regimen (non-TBI/TBI), donor type (matched/mis-
matched), and baseline risk group (high/intermedi-
ate/low). Statistical significance was defined as a P
value less than .05.RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1.
A total of 100 patients participated and underwent
transplantation in this study (April 2005-November
2009). Themedian agewas 47 years (range, 2-61 years),
1528 Biol Blood Marrow Transplant 18:1525-1532, 2012S. W. Choi et al.with 26% of the patients$55 years of age at the time of
transplantation. Seventy-one patients received a mye-
loablative non-TBI-containing conditioning regimen.
These regimens were either busulfan-based (N 5 63)
or BCNU-based (N 5 8). Twenty-nine patients re-
ceived a myeloablative TBI-containing conditioning
regimen.
Toxicity
There were no injection or allergic reactions re-
lated to etanercept. Etanercept was discontinued in 1
patient with primary graft failure after a 7/8-HLAmis-
matched URD bone marrow transplant. The patient
subsequently engrafted after a second transplantation
from the same donor. All other patients engrafted neu-
trophils at a median of 12 days (range, 5-23 days). A to-
tal of 16 patients did not receive 1 or 2 doses due to
persistent fever, a positive blood culture, or inadver-
tent missed dose. In all but 3 patients, the missed doses
occurred either after GVHD had developed or after
day 128, precluding an analysis to determine a mini-
mum number of doses needed to effect outcomes. Eta-
nercept was discontinued early in 5 patients whose
treatment was being held according to study design
and the underlying reason, such as persistent fever,
did not resolve before the third dose was held. Six
patients died before receiving all of the planned study
doses. All of these patients were included in the
analysis.
Infections
Given the importance of TNF-a in the innate im-
mune system [12,21], we monitored infectious
complications in this trial. Stopping rules, which
were never triggered, were in place in the event that
fatal complications exceeded the expected rate
observed in historical controls. Bacteremia was the
most common type of infection in the first 100 days
posttransplantation.Fifty-nine patients developed a to-
tal of 79 bacteremia episodes. Gram-positive organ-
isms, primarily coagulase negative staphylococci,
accounted for 66 (83%) of all culture results. There
were 14 gram-negative organisms isolated in the first
100 days posttransplantation. Bacterial infections ac-
counted for 3 deaths (3%). One patient developed fatal
bacterial pneumonia while receiving etanercept. In 2
additional patients, bacterial septic deaths occurred 5
and 6 weeks after completion of etanercept and during
treatment with high-dose corticosteroids for aGVHD.
To better assess the potential impact of etanercept on
infection risk, we compared the post-engraftment
infection rates during etanercept administration (en-
graftment to day 156) and after etanercept discontin-
uation (day 156 to day 1100). After engraftment, the
relative risk of infection was 1.3 times higher while re-
ceiving etanercept, compared to after discontinuation,but this difference was not statistically significant
(P 5 .36).
A total of 24 patients developed 29 viral reactiva-
tions, most often during treatment with corticoste-
roids for aGVHD. The predominant virus was CMV
(N 5 16). Lethal viral infections developed in 3 pa-
tients while receiving corticosteroids (CMV pneumo-
nia N 5 2, human herpesvirus-6 encephalitis N 5 1).
Invasive fungal infections developed in 3 patients
in the first 180 days posttransplantation. Nine study
patients had a pretransplantation history of invasive
fungal infections (disseminated aspergillus N5 7, liver
candidiasis N 5 1, liver blastomycosis N 5 1). All in-
fections were well-controlled with appropriate anti-
fungal treatment at the time of study entry. Two of
these patients developed radiographic evidence of pro-
gressive fungal pneumonia and died. One additional
patient died of invasive Rhizopus infection on day
195 that developed while being treated with high-
dose corticosteroids for aGVHD.Etanercept Effect on Plasma Ratios of TNFR1
In our previous study, the median day17 TNFR1
level for recipients of myeloablative URD HCT was
1.84 baseline [10]. Therefore, the significantly lower
day 17 TNFR1 ratio of 1.34 (P\ .001; Figure 1A)
that was observed on this clinical trial suggests that
the addition of TNF-blockade to the GVHD prophy-
laxis regimen may have attenuated the expected rise
in TNF levels. Unexpectedly, the effectiveness of
TNF-blockade was confined to patients who received
a non-TBI-containing conditioning regimen (Table 2).
These patients experienced a significantly low day 17
TNFR1 ratio of 1.10 compared with 1.89 in patients
who received a TBI-based conditioning regimen
(P\ .001; Figure 1B). This finding stands out in con-
trast to our previous study in which significant differ-
ences in TNFR1 ratios were not observed between
non-TBI- and TBI-treated patients [10]. Further-
more, these findings cannot be explained on the basis
of differences in baseline TNFR1 levels among study
patients. Themedian baseline TNFR1 level in patients
who received TBI-based conditioning was 1835 pg/mL,
which was not significantly different than the median
level of 1880 pg/mL in patients who received non-
TBI-based conditioning. Moreover, the administra-
tion of palifermin as a radioprotectant to 9 patients
resulted in no apparent effect on the day 17 TNFR1
ratios in TBI-treated patients (2.1 versus 1.8; P 5
NS). Although patients with acute lymphoblastic leu-
kemia were overrepresented and patients with acute
myelogenous leukemia/myelodysplastic syndrome
were underrepresented in the TBI-treated patients,
there were no significant differences in other patient
characteristics, including age, gender, disease status at
transplantation, degree of HLA-match, or stem cell
Figure 1. Day17 tumor necrosis factor receptor 1 (TNFR1) ratio. (A)
The median day 17 TNFR1 ratio of 1.34 in our study population ( ,
N 5 100) was significantly lower than the ratio of 1.84 observed in
our previous study ( , N 5 161), P\.001. (B) Patients who received
a non–total body irradiation (non-TBI)-containing regimen ( , N 5
71) experienced a significantly low day 17 ratio of 1.10 compared to
1.89 in patients who received a TBI-based conditioning regimen ( ,
N 5 29), P\.001.
Table 2. Day +7 TNFR1 Ratios and Transplantation Out-
comes
Day +7 TNFR1
ratio
GVHD
3-4 1-yr NRM 1-yr OS
Overall (N 5 100) 1.34 18% 18% 62%
Non-TBI-treated (N 5 71) 1.10 14% 16% 69%
TBI-treated (N 5 29) 1.89 28% 50% 45%
TNFR1 indicates tumor necrosis factor receptor-1; GVHD, graft-versus-
host disease; NRM, non-relapsemortality; OS, overall survival; TBI, total
body irradiation.
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tients in the current study.
TNF-blockade did not alter the prognostic signif-
icance of a high day17 TNFR1 ratio on outcomes. In
etanercept-treated patients, the day 17 TNFR1 ratio,
when treated as a continuous variable, significantly
correlated with an increased risk of NRM within
1 year (hazard ratio [HR], 1.5; P5 .012) and with a de-
creased likelihood of survival (HR, 1.5; P 5 .027). In-
creased day 17 TNFR1 ratios were also associated
with increased rates of grades 2 to 4 and 3 to 4 aGVHD
(HR, 1.3; P 5 .095; and HR, 1.4; P 5 .082, respec-
tively), although not statistically significant.aGVHD and NRM
The day1100 cumulative incidents of grades 2 to 4
and grades 3 to 4 aGVHD were 45% and 18%, res-
pectively (Figure 2). GVHD requiring treatment was
primarily grade 2 aGVHD (N 5 29) involving only
the skin (N 5 18), upper gastrointestinal (GI; N 5 4),
lower GI (N 5 2), or combined skin and GI (N 5 5).
These patients had a high rate of complete response
to treatment (93%) within a median of 16 days. We
expected to find a lower incidence of aGVHD in the
non-TBI-treated patients compared to TBI-treated
patients based on the lower median day 17 TNFR1
ratio, but the cumulative incidents of grades 2 to 4
aGVHD were the same (45%). There were twice as
many cases of severe grade 3 to 4 GVHD in TBI-
treated patients (28% versus 14%; P 5 .15) in which
TNF blockade was not as effective in attenuating the
day17 TNFR1 ratio, however, this study lacked suffi-
cient power to detect a statistically significant difference
for this comparison.Nevertheless,TBI-treated patients
were more likely to die from GVHD (P 5 .04) and
experienced higher 1-year NRM (50%) compared to
non-TBI-treated patients (16%; P\ .001; Figure 3).
All causes of 1-year NRM are provided (Table 3).
Allo-HCT from HLA-mismatched URDs is asso-
ciated with very high rates of aGVHD and NRM.
Given that over 25% of the study population fell into
this very high-risk category, we analyzed GVHD and
NRMoutcomes for this specific population. The grade
3 to 4 GVHD rates for mismatched URD HCT were
higher than those seen in the other patients (31%versus
14%; P 5 .04), but did not translate into significant
differences in 1-yearNRM (35% versus 22%; P5 .24).Relapse, cGVHD, and OS
The 1-year cumulative incidence of relapse for the
entire study population was 18%, with similar relapse
rates by conditioning regimen administered. The cumu-
lative incidence of cGVHD at 1 year was 48%
(Supplemental Figure 1). With a median follow-up of
15 months (range, 0.7-63 months), the 1-year OS for
the entire study population was 62% (Supplemental
Figure 2). There was a trend toward improved survival
in patients who received a non-TBI-containing regimen
(1-yearOS69%versus45%;P5 .06;Figure3).Notably,
Figure 2. Cumulative incidence of acute graft-versus-host disease
(aGVHD).
1530 Biol Blood Marrow Transplant 18:1525-1532, 2012S. W. Choi et al.the 1-year OS for HLA-mismatched, URD HCT
recipients was not different from HLA-matched URD/
mismatched related donor patients (54% versus 65%;
P 5 .15), even when restricting the analysis to non-
TBI treated patients only (61% versus 71%; P5 .33).Figure 3. One-year non-relapse mortality and overall survival. Non–
total body irradiation (TBI) ( , N 5 71) versus TBI (- - -, N 5 29).DISCUSSION
In this study, the addition of the TNF-inhibitor
etanercept to tacrolimus/methotrexate GVHD
prophylaxis did not affect the overall risk of grades 2
to 4 aGVHD. However, patients who received
a non-TBI-containingmyeloablative unrelated ormis-
matched HCT experienced high rates of steroid-
responsiveness in those who developed GVHD, low
rates of NRM (16%), and good 1-year survival
(69%), and this was associated with lower day 17
TNFR1 ratios. By contrast, there was no apparent ef-
fect of etanercept on day17 TNFR1 ratios, NRM, or
survival in patients who received TBI-containing con-
ditioning regimens. Given the nonrandomized study
design, we cannot conclude with certainty that etaner-
cept administration was responsible for the favorable
outcomes in the non-TBI-conditioned patients. How-
ever, when taken in light of recent observations from
a large series of URD HCT recipients that showed
no significant difference in NRM (31%) and 1-year
survival (51%) betweenTBI and non-TBI-conditioned
patients [22], our findings suggest that etanercept may
have an overall beneficial impact on the outcome after
non-TBIHCT.The reasons for these observations are
not clear.
A possible explanation for our findings in the TBI-
conditioned patients is that high doses of radiation in-
duced greater tissue injury and inflammatory cytokinerelease [23,24] than this dose and schedule of
etanercept was able to effectively neutralize. If so,
a more intensive etanercept dosing regimen may
achieve better results, but further studies would be
needed to evaluate the merits of such a strategy. Data
from animal models demonstrate both TNF-
dependent and TNF-independent pathophysiology,
whereby TNF inhibition attenuates but does not com-
pletely eliminate GVHD [11]. Accordingly, it is also
possible that TNF-independent pathways are major
contributors to GVHD and NRM in radiation-based
conditioning regimens for which even highly effective
TNF inhibition will not significantly alter outcomes.
Given the large difference in 1-year NRM based on
conditioning regimen, we considered the possibility
that TBI-conditioned patients experienced excess
NRM. The 1-year NRM of 50% we observed in
Table 3. Causes of 1-year Non-Relapse Mortality
Causes
Conditioning Regimen
Non-TBI-based
N 5 71
TBI-based
N 5 29
aGVHD and therapy-related complications 8 8
cGVHD and therapy-related complications 2 2
Infection 0 3
Others 3* 2†
Total 13 15
TBI indicates total body irradiation; aGVHD, acute graft-versus-host dis-
ease; cGVHD, chronic graft-versus-host disease.
*Veno-occlusive disease (N 5 2); myocardial infarction (N 5 1).
†Idiopathic pneumonia syndrome (N5 1); central nervous system hem-
orrhage (N 5 1).
Biol Blood Marrow Transplant 18:1525-1532, 2012 1531TNF-Inhibition for GVHD PreventionTBI-conditioned patients is similar to the 43% to 47%
reported in a recently published registry series of over
1200 TBI-conditioned URD recipients [25]. There-
fore, although ineffective, compared with results
reported in the literature, it does not seem that etan-
ercept administration worsened outcomes in TBI-
conditioned patients.
Because TNF-a is an important mediator of both
innate and acquired immune responses [12,21], and
infections represent an established risk of TNF-
inhibitors [26], we paid particular attention to the pos-
sibility that etanercept administration could lead to an
increased number or severity of infections in this im-
munocompromised study population. Infections
within the first 100 days posttransplantationwere com-
mon in this study, as expected in patients undergoing
high-risk allo-HCT [27]. In the absence of a control
population, we are limited in the conclusions we can
draw regarding etanercept and bacterial complications.
It is encouraging that the rate of bacteremia, as well as
bacterial septic death (3%), observed in this study is in
line with published rates [28,29]. The incidence and
severity of fungal and viral infections were also what
would be expected in a high-risk population receiving
standard GVHD prophylaxis [30-32]. Importantly,
invasive fungal infections were well-controlled in pa-
tients with a history of such infections or who were un-
dergoing treatment at the time of HCT. The 3 fungal
deaths observed within the first 180 days posttrans-
plantation are in line with published rates of 1% to
5% [33-35]. Nonetheless, further data are needed to
fully assess the safety of etanercept in the context of
prior invasive fungal infections and allo-HCT, partic-
ularly in patients receiving TBI-based conditioning.
Furthermore, our trial design, which mitigated the
risk of infection by monitoring for pathogens early
and initiating preemptive treatments, may have offset
any increased risk due to etanercept.
In summary, this study investigated the addition of
etanercept given twice weekly for the first 8 weeks
posttransplantation to a standard GVHD prophylaxis
regimen. Etanercept injections were well-toleratedand we did not identify any excess toxicity either dur-
ing the 2months of active therapy or the posttreatment
observation period. Based on the lack of efficacy ob-
served in patients receiving TBI-based conditioning,
we would caution against the use of etanercept in
this context. Conversely, in nonradiation-based condi-
tioning, etanercept seemed to attenuate the expected
rise in TNFR1 ratios early posttransplantation, and
these patients experienced good outcomes. Future ap-
proaches may build upon a TNF inhibition platform
by incorporating complementary strategies. One
such strategy is to increase the number of regulatory
T cells, which inhibit GVHD while preserving graft-
versus-lymphoma [28]. An experimental GVHD
model has demonstrated that extracorporeal photo-
pheresis induces regulatory T cells [29].We are, there-
fore, currently testing this combination approach of
TNF inhibition and extracorporeal photopheresis in
a prospective clinical trial in URD HCT.ACKNOWLEDGMENTS
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